Sarah M Bray

US Patent:

20090246174, Oct 1, 2009

Filed:

Dec 28, 2006

Appl. No.:

12/159058

Inventors:

Alain H. Rook - Wynnewood PA, US
Bernice M. Benoit - Prospect Park PA, US
Maria Wysocka - Drexel Hill PA, US
Sarah M. Bray - Pittsburgh PA, US
Richard L. Miller - Maplewood MN, US
Mark A. Tomai - Woodbury MN, US

International Classification:

A61K 38/21
C12N 5/06
A61K 31/4745

US Classification:

424 855, 435375, 514293, 424 857

Abstract:

The present invention provides method for treating a patient with cutaneous T cell lymphoma (CTCL). Generally, the methods include administering to the patient an IRM compound in an amount effective to ameliorate at least one symptom or clinical sign of CTCL. In some embodiments, the methods also include administering to the patient a priming dose of a Type I interferon. In another aspect, the invention provides methods of increasing a cell-mediated immune response of a cell population that includes cells affected by cutaneous T cell lymphoma. Generally, the methods include contacting the cell population with an IRM compound in an amount effective to increase at least one cell-mediated immune activity of the cell population. In some embodiments, the methods include contacting the cell population with a priming dose of a Type I interferon.

US Patent:

20170340612, Nov 30, 2017

Filed:

Aug 16, 2017

Appl. No.:

15/678457

Inventors:

- Saint Paul MN, US
BERNICE M. BENOIT - PROSPECT PARK PA, US
MARIA WYSOCKA - DREXEL HILL PA, US
SARAH M. BRAY - PITTSBURGH PA, US
RICHARD L. MILLER - MAPLEWOOD MN, US
MARK A. TOMAI - WOODBURY MN, US

Assignee:

3M INNOVATIVE PROPERTIES COMPANY - SAINT PAUL MN

International Classification:

A61K 31/4164
A61K 31/417

Abstract:

The present invention provides method for treating a patient with cutaneous T cell lymphoma (CTCL). Generally, the methods include administering to the patient an IRM compound in an amount effective to ameliorate at least one symptom or clinical sign of CTCL. In some embodiments, the methods also include administering to the patient a priming dose of a Type I interferon. In another aspect, the invention provides methods of increasing a cell-mediated immune response of a cell population that includes cells affected by cutaneous T cell lymphoma. Generally, the methods include contacting the cell population with an IRM compound in an amount effective to increase at least one cell-mediated immune activity of the cell population. In some embodiments, the methods include contacting the cell population with a priming dose of a Type I interferon.